2-propanol has been researched along with irinotecan in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Huang, Z; Zhang, Y | 1 |
| Fukunaga, H; Ichikawa, Y; Kim, HM; Kimura, H; Kondou, S; Matsuo, Y; Morita, S; Murakami, M; Sawada, G; Shirai, S; Takada, A | 1 |
3 other study(ies) available for 2-propanol and irinotecan
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Iris metastasis as resistance mechanism to atezolizumab, carboplatin, and etoposide but responds to additional irinotecan and anlotinib in a small cell lung cancer patient.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blindness; Carboplatin; Carcinoma, Small Cell; Etoposide; Female; Humans; Irinotecan; Iris; Lung Neoplasms; Small Cell Lung Carcinoma | 2023 |
[A Case of Rectal Neuroendocrine Carcinoma with Iris Metastasis].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Humans; Irinotecan; Iris; Male; Middle Aged; Rectal Neoplasms; Rectum | 2023 |